πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 650 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9572802

Diamide compounds having muscarinic receptor antagonist and Ξ²2 adrenergic receptor agonist

Theravance Respiratory Company, LLC Β· Granted Tue Feb 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9574004

Methods for treating or preventing asthma by administering an IL-4R antagonist

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9567566

HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants

The United States of America as Represented by the Secretary, Dept. of Health and Human Services Β· Granted Tue Feb 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9562039

Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both Ξ²2 adr

Almirall, S.A. Β· Granted Tue Feb 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9556133

Polycyclic LPA1 antagonist and uses thereof

AMIRA PHARMACEUTICALS, INC. Β· Granted Tue Jan 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9549934

Cyclohexylamine derivatives having Ξ²2 adrenergic agonist and M3 muscarinic antagonist acti

Almirall, S.A. Β· Granted Tue Jan 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9550742

11-OXO-10,11-dihydrodibenzo[B,F][1,4]thiazepine S-oxide derivatives and their use as dopam

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jan 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9550818

Methods for use of vascular endothelial growth factor antagonists

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jan 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9518091

A4B7 peptide monomer and dimer antagonists

Protagonist Therapeutics, Inc. Β· Granted Tue Dec 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9518050

Cyclohexyl and quinuclidinyl carbamate derivatives having Ξ²2 adrenergic agonist and M3 mus

Almirall, S.A. Β· Granted Tue Dec 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9517228

Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders,

Jenrin Discovery, LLC Β· Granted Tue Dec 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9511140

Stable VEGF antagonist formulations

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9493467

PI3 kinase antagonists

The Regents of the University of California Β· Granted Tue Nov 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9493564

CD86 antagonist multi-target binding proteins

Aptevo Research and Development LLC Β· Granted Tue Nov 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9468624

Small molecule antagonists of bacterial quorum-sensing receptors

THE TRUSTEES OF PRINCETON UNIVERSITY Β· Granted Tue Oct 18 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 13 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9452161

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance Biopharma R&D IP, LLC Β· Granted Tue Sep 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9441041

Use of antagonists of the interaction between HIV GP120 and Ξ±4Ξ²7 integrin

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Sep 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9428467

Selective calcium channel antagonists

Northwestern University Β· Granted Tue Aug 30 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9422310

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

Neurocrine Biosciences, Inc. Β· Granted Tue Aug 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9416167

Stable liquid formulations of dimer VEGF antagonists

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 16 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9394275

Diamide compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agon

Theravance Respiratory Company, LLC Β· Granted Tue Jul 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9365540

Benzimidazole derivatives as MCH receptor antagonists

Takeda Pharmaceutical Company Limited Β· Granted Tue Jun 14 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9353108

Tetrahydronaphthyridine somatostatin receptor 5 antagonists

Takeda Pharmaceutical Company Limited Β· Granted Tue May 31 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9353175

Use of antagonists targeting metallothionein to treat intestinal inflammation

UNIVERSITY OF CONNECTICUT Β· Granted Tue May 31 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted